New Study Investigates Cerebral Oxygenation Normative Values Using Masimo O3® Regional Oximetry
Masimo (NASDAQ: MASI) announced today the findings of a study, recently published in Anaesthesia and Intensive Care, in which researchers at Austin Hospital in Melbourne, Australia sought to measure cerebral oxygenation in a large cohort of healthy volunteers, using Masimo O3® Regional Oximetry, to establish a normal range of values and investigate the relationship between cerebral oxygenation and other physical and hemodynamic characteristics.1 O3 uses near-infrared spectroscopy (NIRS) to monitor cerebral oxygenation in situations in which peripheral pulse oximetry alone may not be fully indicative of the oxygen in the brain.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190414005060/en/
Masimo Root® with O3® Regional Oximetry and Next Generation SedLine® Brain Function Monitoring (Graphic: Business Wire)
Noting that “normative values for clinical devices are essential to allow for definition of abnormality during clinical use” and that available regional cerebral tissue oxygen saturation (SctO2) reference values have limitations, including not taking into account variables such as brain hemisphere, sex, skin type, height, weight, and others, Dr. Christopher Eyeington and colleagues used Masimo O3 to assess for differences in SctO2 between hemispheres, sex, and comorbidity and smoking status, and for associations between SctO2 and key physical and hemodynamic characteristics, in healthy adults. They enrolled 98 volunteers, 22-60 years old, including 41 males, 22 with one or more co-morbidities, 13 current or former smokers, and with a variety of skin types. Each volunteer was monitored continuously for five minutes using O3 on the Masimo Root® Patient Monitoring and Connectivity Hub, with SctO2 measurements recorded every two seconds.
The researchers recorded 32,130 SctO2 observations. Mean left, right, and combined average SctO2 values were 67.3%, 67.9%, and 67.6%, respectively, with a “narrow” combined average 95% confidence interval of 66.8% to 68.6%. (None of the 95% confidence intervals was lower than 66.5% or greater than 69.1%.) The researchers found “statistically significant yet quantitatively small differences” in SctO2 values according to hemisphere (p < 0.001). They also found that increasing mean arterial pressure (MAP) (p = 0.001) and cardiac index (CI) (p ≤ 0.001) were associated with increased SctO2: each 10 mmHg increase in MAP and 1 L/min/m2 increase in CI was associated with 0.01% and 0.1% increases in SctO2, respectively.
The researchers noted, “Our study implies that in healthy adults the mean SctO2 measured with modern technology is close to 68% with narrow confidence intervals of 1%, and with no difference between hemispheres. Moreover, given a lowest mean combined bi-hemispheric SctO2 value of 56%, it implies that an SctO2 value below 56% should be considered ‘abnormally low.’ In addition, the very few SctO2 values below 60% seen in our study imply that persistent measurements below such a threshold should be viewed with concern. Finally, our observation that SctO2 values were not affected in any clinically significant amount by hemispheres, sex, skin type, comorbidity or smoking status, age or any haemodynamic parameter implies that in healthy adults, cerebral tissue oxygen saturation is unaffected by these factors.” They concluded that “These findings have significant implications regarding the clinical interpretation of SctO2 and the application of this information to individual patients.”
Study co-author Dr. Rinaldo Bellomo commented, “The estimation of cerebral oxygenation by near infrared spectroscopy (NIRS) during anesthesia or in critical illness is becoming increasingly recognized as a desirable form of monitoring. Thus, it is vital for clinicians to understand normal values and to have confidence in the technology behind such measurements. The recent study by my colleagues and myself used >30,000 observations in close to 100 normal subjects and found that the mean normal value for cerebral oxygen estimation using modern Masimo NIRS technology was 67.6%, and, more importantly, that the 95% confidence interval for such value was narrow, between 66.8% and 68.6%. Such findings provide a reference value for patient assessment and give a degree of confidence to clinicians in relation to the validity and robustness of this technology.”
@MasimoInnovates | #Masimo
Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive monitoring technologies. Our mission is to improve patient outcomes and reduce the cost of care. In 1995, the company debuted Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, which has been shown in over 100 independent and objective studies to outperform other pulse oximetry technologies.2 Masimo SET® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates,3 improve CCHD screening in newborns,4 and, when used for continuous monitoring with Masimo Patient SafetyNet™ in post-surgical wards, reduce rapid response activations and costs.5-7 Masimo SET® is estimated to be used on more than 100 million patients in leading hospitals and other healthcare settings around the world,8 and is the primary pulse oximetry at 9 of the top 10 hospitals listed in the 2018-19 U.S. News and World Report Best Hospitals Honor Roll.9 In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVi®), and more recently, Oxygen Reserve Index (ORi™), in addition to SpO2, pulse rate, and perfusion index (Pi). In 2014, Masimo introduced Root®, an intuitive patient monitoring and connectivity platform with the Masimo Open Connect® (MOC-9®) interface, enabling other companies to augment Root with new features and measurement capabilities. Masimo is also taking an active leadership role in mHealth with products such as the Radius-7® wearable patient monitor, iSpO2 ® pulse oximeter for smartphones, and the MightySat™ fingertip pulse oximeter. Additional information about Masimo and its products may be found at www.masimo.com. Published clinical studies on Masimo products can be found at http://www.masimo.com/evidence/featured-studies/feature/.
ORi has not received FDA 510(k) clearance and is not available for sale in the United States. The use of the trademark Patient SafetyNet is under license from University HealthSystem Consortium.
- Eyeington C, Ancona P, Osawa E, Cutuli S, Eastwood G and Bellomo R. Modern technology-derived normative values for cerebral tissue oxygen saturation in adults. Anaesthesia and Intensive are. 2019. DOI: 10.117.7/0310057X18811962.
- Published clinical studies on pulse oximetry and the benefits of Masimo SET® can be found on our website at http://www.masimo.com. Comparative studies include independent and objective studies which are comprised of abstracts presented at scientific meetings and peer-reviewed journal articles.
- Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm Infants through Changes in Clinical Practice and SpO2 Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
- de-Wahl Granelli A et al. Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ. 2009;Jan 8;338.
- Taenzer AH et al. Impact of pulse oximetry surveillance on rescue events and intensive care unit transfers: a before-and-after concurrence study. Anesthesiology. 2010:112(2):282-287.
- Taenzer A et al. Postoperative Monitoring – The Dartmouth Experience. Anesthesia Patient Safety Foundation Newsletter. Spring-Summer 2012.
- McGrath SP et al. Surveillance Monitoring Management for General Care Units: Strategy, Design, and Implementation. The Joint Commission Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302.
- Estimate: Masimo data on file.
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among others, statements regarding the potential effectiveness of Masimo O3®. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo's unique noninvasive measurement technologies, including Masimo O3, contribute to positive clinical outcomes and patient safety; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions and unique advantages; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Wenco and Hitachi Construction Machinery Announce Open and Interoperable Partner Ecosystem for Autonomous Mining25.4.2019 23:30:00 CEST | Pressemelding
Hitachi Construction Machinery Co., Ltd. (TOKYO: 6305) (“HCM”) is pleased to announce its vision for autonomous mining — an open, interoperable ecosystem of partners that integrate their systems alongside existing mine infrastructure. Grounded in support for ISO Standards and a drive to encourage new entrants into the mining industry, HCM is pioneering this open and interoperable approach to autonomy among global mining technology leaders. With this announcement, HCM is publicly declaring support for standards-based autonomy and is offering its interoperable technology to assist mining customers in integrating new vendors into their existing infrastructure. HCM’s support for open, interoperable autonomy is based on its philosophy for its partner-focused Solution Linkage platform. “Open innovation is the guiding technological philosophy for Solution Linkage,” says Vice President and Executive Officer, Chief Technology Officer Hideshi Fukumoto. “Based on this philosophy, HCM is announcin
Garth Brooks Makes Mobile Game Debut in Words With Friends, Announces Final Pre-Order Window for The Legacy Collection25.4.2019 19:30:00 CEST | Pressemelding
Today, Zynga Inc. (Nasdaq: ZNGA), global leader in interactive entertainment, announced a collaboration with Garth Brooks, in its hit game, Words With Friends 2 . Kicking off a multi-month celebration of the game franchise’s 10th anniversary, and Brooks’ unprecedented career as a recording artist, players and fans will be treated to Garth-themed in-game activities and ongoing announcements starting with today’s reveal of ‘Journey’ as the game’s ‘Word of the Year’. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190425005903/en/ Garth Brooks LEGACY COLLECTION (Graphic: Business Wire) Garth Brooks and Words With Friends are celebrating their 2019 milestones by giving fans new ways to interact with Garth and the game. On May 1st, Brooks will co-host Words With Friends LIVE, the nightly trivia game broadcast within Words With Friends 2. In conjunction, the FINAL pre-order window for special numbered editions of The Legacy Collect
Nordson EFD Introduces the Contact versus Jet Dispensing White Paper25.4.2019 12:16:00 CEST | Pressemelding
Nordson EFD , a Nordson company (NASDAQ: NDSN), the world’s leading precision fluid dispensing systems manufacturer, is pleased to introduce its Contact vs. Jet Dispensing white paper. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190425005027/en/ As products continue to get smaller and smaller, Nordson EFD has developed new solutions to address this growing need to apply precise, repeatable micro-deposits of assembly fluids in production processes worldwide. “We understand the challenges manufacturers face when their process requires bonding tiny substrates and components together,” said Peter Langer, Business Unit Director of Valves at Nordson EFD. “The deposit tolerance requirements are considerable. And there are a number of variables to consider in order to choose the right dispensing method.” This white paper helps manufacturers understand the difference between two of the most common dispensing methods. Contact dispe
Hologic Launches Trident® HD Specimen Radiography System in United States, Canada and Europe25.4.2019 12:15:00 CEST | Pressemelding
Hologic, Inc. (Nasdaq: HOLX) today announced global commercial availability of the Trident® HD specimen radiography system, a next-generation solution that delivers enhanced image quality, improved workflow and instant sample verification during breast-conserving surgeries and stereotactic breast biopsies.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190425005180/en/ Trident® HD Specimen Radiography System (Photo: Business Wire) The Trident products are the only specimen radiographs on the market to use amorphous selenium direct capture imaging – the same detector technology used in Hologic’s 3Dimensions™ mammography system – to generate crisp, clear, high-resolution images. The new Trident HD system, which recently received FDA clearance in the US and a CE Mark in Europe, also features a bigger detector that allows for complete imaging of larger breast surgical specimens, along with a wide range of surgical and biopsy sa
Velodyne Lidar, Nikon Announce Manufacturing Agreement for Mass Production of Velodyne Lidar Sensors25.4.2019 12:00:00 CEST | Pressemelding
Velodyne Lidar, Inc. today announced an agreement with Nikon Corporation, under which Sendai Nikon Corporation, a Nikon subsidiary, will manufacture lidar sensors for Velodyne with plans to start mass production in the second half of 2019. The partnership cements Velodyne’s manufacturing plan and expands its lead in the global lidar sensor market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190425005236/en/ Velodyne provides the smartest, most powerful lidar solutions for vehicle autonomy and driver assistance. (Photo: Business Wire) “Mass production of our high-performance lidar sensors is key to advancing Velodyne’s immediate plans to expand sales in North America, Europe, and Asia,” said Marta Hall, President and CBDO, Velodyne Lidar. “With this partnership, Velodyne affirms its leadership role in designing, producing, and selling lidar for worldwide implementation. For years, Velodyne has been perfecting lidar technol
Gilead Announces Topline Data From Phase 3 STELLAR-3 Study of Selonsertib in Bridging Fibrosis (F3) Due to Nonalcoholic Steatohepatitis (NASH)25.4.2019 12:00:00 CEST | Pressemelding
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that STELLAR-3, a Phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of selonsertib, an investigational, once daily, oral inhibitor of apoptosis signal-regulating kinase 1 (ASK1), for patients with bridging fibrosis (F3) due to nonalcoholic steatohepatitis (NASH), did not meet the pre-specified week 48 primary endpoint of a ≥ 1-stage histologic improvement in fibrosis without worsening of NASH. In the study of 802 enrolled and dosed patients, 9.3 percent of patients treated with selonsertib 18 mg (p=0.42 versus placebo) and 12.1 percent of patients treated with selonsertib 6 mg (p=0.93) achieved a ≥ 1-stage improvement in fibrosis according to the NASH Clinical Research Network (CRN) classification without worsening of NASH after 48 weeks of treatment, versus 13.2 percent with placebo. Selonsertib was generally well tolerated and safety results were consistent with prior studies. “While we